Clinical trials · Texas
Multiple myeloma clinical trials in Texas
We’re tracking 61 recruiting multiple myeloma studies with a site in Texas — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Texas
- NCT07280013RecruitingPhase 1
Cemsidomide with elranatamab for multiple myeloma
This trial tests a new drug combination (cemsidomide and elranatamab) for people with multiple myeloma that has come back after previous treatments. The goal is to see if the combination is safe and works better than current options.
Dallas, TexasAges 18 years+ - NCT05722418RecruitingPhase 1
CRISPR-edited CAR-T for harder-to-treat myeloma
This Phase 1 study tests a lab-made immune cell therapy (CAR-T) made from a donor, with a CRISPR edit, for multiple myeloma that has come back or not responded to treatment. It aims to find the safest way to give the treatment and see how well it can control the cancer.
Dallas, TexasAges 18 years+ - NCT05776979RecruitingPhase 2
Isatuximab plus lenalidomide after transplant for high-risk myeloma
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
Houston, TexasAges 18–72 - NCT06057402RecruitingPhase 4
Continued access to elranatamab for multiple myeloma
This trial offers continued access to elranatamab for people with multiple myeloma who were already benefiting from it in a previous study and whose earlier study ended.
Austin, TexasAges 18 years+ - NCT06365060Recruiting
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
This study is screening people with smoldering multiple myeloma or a monoclonal gammopathy to see if they might have an early form of AL amyloidosis, a condition where abnormal proteins build up in organs. If you meet the criteria, you will be tested to find out if you have amyloidosis, which could help catch it early.
Dallas, TexasAges 40 years+ - NCT06953960RecruitingPhase 1/Phase 2
Surzetoclax for multiple myeloma with or without other drugs
This trial tests a new oral drug called surzetoclax, alone or with other myeloma treatments, for people with a specific type of multiple myeloma. It aims to see if the drug is safe and helps control the disease.
Dallas, TexasAges 18 years+ - NCT05730036RecruitingPhase 3
Linvoseltamab vs standard treatment for relapsed myeloma
This trial compares linvoseltamab against a standard combination (elotuzumab + pomalidomide + dexamethasone) in adults with multiple myeloma that has returned or not responded. It aims to find out whether linvoseltamab works better and is safe for people who have already had some myeloma treatments.
Houston, TexasAges 18 years+ - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Dallas, TexasAges 18 years+ - NCT05850234RecruitingPhase 1/Phase 2
Study drug for hard-to-treat multiple myeloma after prior treatments
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
Dallas, TexasAges 18 years+ - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Austin, TexasAges 18 years+ - NCT07222761RecruitingPhase 3
Comparing new treatments for relapsed multiple myeloma
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
Houston, TexasAges 18 years+ - NCT05231629RecruitingPhase 2
MRD-guided step-by-step treatment for multiple myeloma
This Phase 2 study tests a treatment plan for newly diagnosed multiple myeloma that changes based on MRD results. MRD is a very sensitive lab test that looks for tiny amounts of remaining cancer, which may help tailor therapy to work better and potentially avoid overtreatment.
Dallas, TexasAges 18 years+ - NCT05519085RecruitingPhase 3
Test mezigdomide vs pomalidomide with standard drugs for myeloma
This Phase 3 study compares two combination treatments for multiple myeloma that has come back or not gone away (relapsed or refractory). It aims to see whether mezigdomide, along with bortezomib and dexamethasone, works better than pomalidomide with those same medicines.
Abilene, TexasAges 18 years+ - NCT07095452RecruitingPhase 2/Phase 3
Newly diagnosed myeloma: comparing drug combinations for non-transplant patients
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
The Woodlands, TexasAges 18 years+ - NCT05243797RecruitingPhase 3
Teclistamab plus lenalidomide maintenance after transplant
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
Houston, TexasAges 18 years+ - NCT06615479RecruitingPhase 3
New treatment vs standard care for relapsed multiple myeloma
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
Houston, TexasAges 18 years+ - NCT05828511RecruitingPhase 1/Phase 2
Study drug for newly diagnosed myeloma before standard treatment
This trial tests linvoseltamab (a new targeted immune treatment) to see if it’s safe and how well it works in adults with recently diagnosed multiple myeloma who haven’t started treatment yet. Because it’s a “window of opportunity” study, it’s meant to learn early results before standard therapy is fully underway.
Houston, TexasAges 18 years+ - NCT05623020RecruitingPhase 3
New treatment for newly diagnosed transplant-ineligible myeloma
This Phase 3 study compares a three-drug combination (elranatamab, daratumumab, and lenalidomide) versus a standard three-drug treatment (daratumumab, bortezomib, lenalidomide, plus dexamethasone). It aims to see which plan works better for people newly diagnosed with multiple myeloma who cannot get a stem cell transplant.
Houston, TexasAges 18 years+ - NCT05137054RecruitingPhase 1
Linvoseltamab combo for hard-to-treat multiple myeloma
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
Dallas, TexasAges 18 years+ - NCT05652335RecruitingPhase 1
JNJ-79635322 for hard-to-treat myeloma or amyloidosis
This Phase 1 study tests how safe and how well JNJ-79635322 works in people with multiple myeloma that has come back or is resistant to treatment, or AL amyloidosis that has already been treated. It may help by targeting cancer cells and abnormal proteins driving these diseases.
Houston, TexasAges 18 years+ - NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
Dallas, TexasAges 18 years+ - NCT06152575RecruitingPhase 3
Study of elranatamab for multiple myeloma that returned after other treatments
This trial tests a new medicine called elranatamab in people whose multiple myeloma has come back after they tried other treatments, including a specific type of immunotherapy (anti-CD38) and the drug lenalidomide. The goal is to see if this medicine can help control the cancer.
Dallas, TexasAges 18 years+ - NCT05055063RecruitingPhase 1
Belantamab for high-risk smoldering myeloma safety and early benefit
This Phase 1 trial tests belantamab mafodotin, a cancer medicine, in people with high-risk smoldering multiple myeloma to see how safe it is and whether it may shrink or control the disease. Because it’s an early-stage study, you would be closely monitored and treated with one main study drug.
Houston, TexasAges 18 years+ - NCT06536413RecruitingPhase 1/Phase 2
ATRA and Carfilzomib for multiple myeloma
This trial tests if combining the drug ATRA with carfilzomib can help people with multiple myeloma whose cancer has come back or stopped responding to at least three prior treatments, including carfilzomib. The goal is to see if this new combination works better than carfilzomib alone.
Houston, TexasAges 18 years+
Multiple myeloma trials by city in Texas
Where these studies are running in Texas
Institutions with a site for the recruiting multiple myeloma studies listed above.
- The University of Texas MD Anderson Cancer Center · 7 studies
- University of Texas Southwestern Medical Center · 5 studies
- Houston Methodist Hospital · 4 studies
- Research Site · 3 studies
- Baylor University Medical Center · 2 studies
- Baylor Scott & White Medical Center – Temple
- Houston Methodist Sugar Land Hospital
- Houston Methodist The Woodlands Hospital
What taking part in a multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Multiple myeloma trials in other states
Common questions
- Are there multiple myeloma clinical trials in Texas?
- Yes. We're currently tracking 61 recruiting multiple myeloma studies with a site in Texas, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a multiple myeloma study in Texas?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Texas to take part?
- Not necessarily. These studies have a site in Texas, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New multiple myeloma studies open in Texas regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.